CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Moderna, Inc.

MRNA
$73.74BLarge Cap

Next catalyst

Phase 2November 2026

mRNA-3745

Glycogen Storage Disease

Get an email about MRNA's next catalysts

Track Moderna (MRNA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 4 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

5 upcoming, 1 past

Phase 2Next

mRNA-3745 Phase 2 Est. Readout

November 2026~mRNA-374515

Primary completion for mRNA-3745 trial (NCT05095727) in Glycogen Storage Disease

Source
Phase 3

mRNA-1018-H5 Phase 3 Est. Readout

January 2027~mRNA-1018-H54,050

Estimated primary completion for mRNA-1018-H5 trial (NCT07496450) in Influenza. Topline data typically follows completion by weeks to months.

Source
Phase 3

mRNA-1403 Phase 3 Est. Readout (Nova 301)

February 2027~mRNA-140337,864

Primary completion for mRNA-1403 trial (NCT06592794) in Acute Gastroenteritis

Source
Phase 2

mRNA-1647 Phase 2 Est. Readout

March 2027~mRNA-164784

Primary completion for mRNA-1647 trial (NCT05575492) in Cytomegalovirus

Source
Phase 2

mRNA-3927 Phase 2 Est. Readout

Q3 2027~QmRNA-392777

Primary completion for mRNA-3927 trial (NCT04159103) in Propionic Acidemia

Source

How MRNA's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE4.8K employees

Moderna, Inc. (/məˈdɜːrnə/ mə-DUR-nə) is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Website
Drug Pipeline

mRNA-1273.214

Phase 3

SARS-CoV-2

mRNA-1083

Phase 3

COVID-19

mRNA-1283.815

Phase 3

COVID-19

mRNA-1283.222

Phase 3

COVID-19

mRNA-1345

Phase 3

Respiratory Syncytial Virus

mRNA-4157

Personalized Cancer Vaccine

Phase 3

Melanoma

OrphanFast TrackBreakthrough

Pfizer-BioNTech COVID-19 Vaccine BNT162b2 (Comirnaty®)

Phase 3

Immunocompromised Patients

Fluarix Tetra

Phase 3

Seasonal Influenza

Afluria® Quadrivalent

Phase 3

Respiratory Syncytial Virus

mRNA-1403

Phase 3

Acute Gastroenteritis

Pembrolizumab coformulated with berahyaluronidase alfa

Phase 3

Non-small Cell Lung Cancer

mRNA-1273.211

Phase 3

SARS-CoV-2

mRNA-1273.213

Phase 3

SARS-CoV-2

mRNA-1010

Phase 3

Seasonal Influenza

Fast Track

mRNA-1273.529

Phase 3

SARS-CoV-2

mRNA-1273

Phase 3

SARS-CoV-2

mRNA-1273.231

Phase 3

SARS-CoV-2

Fluzone HD

Phase 3

Respiratory Syncytial Virus

Influenza Vaccine

Phase 3

SARS-CoV-2

Fluarix®

Phase 3

Seasonal Influenza

mRNA-1273.617.2

Phase 3

SARS-CoV-2

mRNA-1273.222

Phase 3

COVID-19

mRNA-1273.815

Phase 3

COVID-19

Investigational mRNA-1273.815

Phase 3

SARS-CoV-2

Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine

Phase 3

Seasonal Influenza

mRNA-1018-H5

Phase 3

Influenza

Intismeran autogene

Phase 3

Non-small Cell Lung Cancer

Influsplit® Tetra

Phase 3

Seasonal Influenza

Moderna COVID-19 Vaccine, mRNA-1273

Phase 3

Immunocompromised Patients

mRNA-1283

Phase 3

COVID-19

Fast Track

mRNA-1083 Composition 1 Dose B

Phase 2

Influenza

mRNA-1083.2

Phase 2

SARS-CoV-2

mRNA-1045

Phase 2

Influenza

mRNA-1283.529

Phase 2

SARS-CoV-2

mRNA-1083 Composition 3 Dose B

Phase 2

Influenza

mRNA-1018 for H5 Only

Phase 2

Influenza

mRNA-1083 Composition 1 Dose A Lot B

Phase 2

Influenza

mRNA-1083 Composition 2 Dose A

Phase 2

Influenza

BEXSERO

Phase 2

Genital Herpes

mRNA-1011.2

Phase 2

Seasonal Influenza

mRNA-1018 for H5 Only-CG

Phase 2

Influenza

mRNA-1018 for H7N9

Phase 2

Influenza

mRNA-1083.3

Phase 2

SARS-CoV-2

mRNA-1083 Composition 1 Dose C

Phase 2

Influenza

mRNA-1083 Composition 3 Dose A

Phase 2

Influenza

mRNA-1010.6

Phase 2

Influenza

mRNA-1018 for H7 Only

Phase 2

Influenza

mRNA-1083 Composition 2 Dose B

Phase 2

Influenza

mRNA-1012.1

Phase 2

Seasonal Influenza

mRNA-1020

Phase 2

Seasonal Influenza

mRNA-1647

Phase 2

Cytomegalovirus Infection

mRNA-1030

Phase 2

Seasonal Influenza

mRNA-1769

Phase 2

Smallpox

mRNA-1608

Phase 2

Genital Herpes

mRNA-1018 for H5N8

Phase 2

Influenza

mRNA-3927

Phase 2

Propionic Acidemia

mRNA-1073

Phase 2

SARS-CoV-2

mRNA-1283.211

Phase 2

SARS-CoV-2

mRNA-1468

Phase 2

Herpes Zoster

mRNA-1893

Phase 2

Zika Virus

mRNA-1083 Composition 1 Dose A Lot A

Phase 2

Influenza

mRNA-3705

Phase 2

Methylmalonic Acidemia

mRNA-3745

Phase 2

Glycogen Storage Disease

mRNA-1010.4

Phase 2

Influenza

Egg-based Quadrivalent Influenza Vaccine

Phase 2

Influenza

mRNA-1195

Phase 2

Multiple Sclerosis

mRNA-1011.1

Phase 2

Seasonal Influenza

mRNA-1405

Phase 2

Norovirus Acute Gastroenteritis

mRNA-1189

Phase 2

Epstein-Barr Virus Infection

mRNA-1975

Phase 2

Lyme Disease

Influenza Vaccine 1

Phase 2

SARS-CoV-2

mRNA-2808

Phase 2

Relapsed or Refractory Multiple Myeloma

mRNA-1982

Phase 2

Lyme Disease

mRNA-1273.214 Vaccine

Phase 2

COVID-19 Pandemic

mRNA-1273.351

Phase 2

SARS-CoV-2

mRNA-4359

Phase 2

Advanced Solid Tumors

IVA

Phase 2

Cystic Fibrosis

mRNA-1083.1

Phase 2

SARS-CoV-2

Frequently asked questions

What is in Moderna, Inc.'s drug pipeline?→

CatalystAlert tracks 78 drug candidates in Moderna, Inc.'s (MRNA) pipeline across Phase 3, Phase 2. Its lead program is mRNA-1018-H5 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Moderna, Inc.'s next FDA catalyst?→

Moderna, Inc.'s (MRNA) next tracked catalyst is a Phase 2 readout expected November 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track MRNA biotech catalysts?→

Add MRNA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Moderna, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply